Oral Session 2-7C ATL: Treatment

[OS2-7C-2] Aggressive ATL prospective cohort study: CB and haploidentical transplantation may be feasible

Ayumu Ito¹, Nobuaki Nakano², Takashi Tanaka¹, Shigeo Fuji³, Junya Makiyama⁴, Yoshitaka Inoue⁵, Ilseung Choi⁶, Hirohisa Nakamae⁷, Koji Nagafuji⁸, Ken Takase⁹, Shinichiro Machida¹⁰, Tsutomu Takahashi¹¹, Yasushi Sawayama¹², Tomohiko Kamimura¹³, Koji Kato¹⁴, Toshiro Kawakita¹⁵, Masao Ogata¹⁶, Rika Sakai¹⁷, Souichi Shiratori¹⁸, Yoshihiro Inamoto¹, Kaoru Uchimaru¹⁹, Atae Utsunomiya², Takahiro Fukuda¹ (1.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, 2.Hematology, Imamura General Hospital, Kagoshima, Japan, 3.Hematology, Osaka International Cancer Institute, Osaka, Japan, 4.Hematology/Oncology, IMSUT Hospital, Tokyo, Japan, 5.Hematology, Kumamoto University Hospital, Kumamoto, Japan, 6.Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 7.Hematology, Osaka City University Hospital, Osaka, Japan, 8.Hematology and Oncology, Kurume University Hospital, Fukuoka, Japan, 9.Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, 10.Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan, 11.Oncology/Hematology, Shimane University Hospital, Shimane, Japan, 12.Hematology, Nagasaki University Hospital, Nagasaki, Japan, 13.Hematology, Harasanshin Hospital, Fukuoka, Japan, 14.Hematology, Oncology and Cardiovascular medicine, Kyushu University Hospital, Fukuoka, Japan, 15.Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan, 16.Hematology, Oita University Hospital, Oita, Japan, 17.Hematology and Medical Oncology, Kanagawa Cancer Center, Kanagawa, Japan, 18.Hematology, Hokkaido University Hospital, Sapporo, Japan, 19.Graduate School of Frontier Sciences, The University of Tokyo, Japan)